Clinical Trial Update: A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems [Phase 1]

View source ↗

Summary

Phase 1 study of Novo Nordisk's insulin analogue NNC0148-0287 C (Insulin 287) has completed, evaluating its safety and pharmacology in individuals with Type 2 d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin 287 (NNC0148-0287 C) (NNC0148-0287 C)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED